These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 2503895)

  • 41. Bioequivalence and pharmacodynamics of a modified glibenclamide formulation in healthy volunteers.
    Molz KH; Klimmek R; Dilger C; Pabst G; Weber W; Müller M; Jaeger H
    Arzneimittelforschung; 1989 Oct; 39(10):1280-2. PubMed ID: 2514694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients.
    Kyllästinen M; Groop L
    Ann Clin Res; 1985; 17(3):100-4. PubMed ID: 3931537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative bio-availability of theophylline whole and halved sustained-release tablets.
    Müller FO; Hundt HK; Luus HG; van Dyk M; Groenewoud G; van der Meer MJ; Steinijans VW
    S Afr Med J; 1987 Aug; 72(3):175-8. PubMed ID: 3299763
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioequivalence of two oral formulations of glyburide (glibenclamide).
    Flores-Murrieta FJ; Carrasco-Portugal Mdel C; Reyes-García G; Medina-Santillán R; Herrera JE
    Proc West Pharmacol Soc; 2007; 50():64-6. PubMed ID: 18605232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative bio-availability of four formulations of furosemide.
    Meyer BH; Müller FO; Swart KJ; Luus HG; Werkman IM
    S Afr Med J; 1985 Oct; 68(9):645-7. PubMed ID: 3904040
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide.
    el-Sayed YM; Suleiman MS; Hasan MM; Abdel-Hamid ME; Najib NM; Sallam ES; Shubair MS
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):551-7. PubMed ID: 2515159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].
    Haupt E; Putschky F; Zoltobrocki M; Schöffling K
    Dtsch Med Wochenschr; 1984 Feb; 109(6):210-3. PubMed ID: 6421561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bio-availability of three formulations of glibenclamide.
    Meyer BH; Müller FO; Luus HG; Eckert HG
    S Afr Med J; 1989 Aug; 76(4):146-7. PubMed ID: 2503895
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.